文献速递慢性肾脏病肾血管病与高血压

Lorundrostat 在未控制高血压合并慢性肾脏病及白蛋白尿患者中的 2 期 Explore-CKD 试验结果

Results from the Phase 2 Explore-CKD Trial of lorundrostat, a novel aldosterone synthase inhibitor, in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria.
PubMed 文献 · Kidney Int · 2026-09-23

本研究为随机、双盲、安慰剂对照、交叉试验,在已稳定使用 RAAS 阻滞剂和 SGLT2i 的未控制高血压合并 CKD 及白蛋白尿成人中评估 lorundrostat 25 mg/日。共 59 例参与者,结果显示 lorundrostat 较安慰剂显著降低自动诊室收缩压(安慰剂校正差 -7.5 mmHg)和尿白蛋白肌酐比(安慰剂校正降低 30.5%),eGFR 有所下降,安全性可接受。

要点

  • lorundrostat 25 mg/日可使未控制高血压合并 CKD 患者 AOSBP 安慰剂校正降低 7.5 mmHg。
  • lorundrostat 使 UACR 几何均值安慰剂校正降低 30.5%,提示潜在心肾获益。
  • lorundrostat 组 eGFR 由 42.9 降至 40.1 mL/min/1.73 m²,需关注肾功能变化。

核心结论

  • 在未控制高血压合并 CKD 及白蛋白尿患者中,lorundrostat 联合 SGLT2i 可降低 AOSBP 和白蛋白尿,安全性可接受。
  • 白蛋白尿的降低可能提示潜在心肾获益,但需更长期研究确定能否转化为持久的肾脏或心血管结局改善。

研究设计与样本

  • 随机、双盲、安慰剂对照、交叉试验,lorundrostat 25 mg/日加用于已使用 SGLT2i 的成人。
  • 纳入未控制高血压、CKD 及白蛋白尿且稳定使用 RAAS 阻滞剂的患者,共 59 例。
  • 参与者随机接受 lorundrostat-安慰剂或安慰剂-lorundrostat 序列,每段治疗 4 周,洗脱期 4 周。
  • 主要终点为自动诊室收缩压(AOSBP)变化,其他终点包括 UACR 和 eGFR 变化。

主要发现

  • 59 例参与者平均年龄 64.6 岁,平均 BMI 33 kg/m²,76% 合并 2 型糖尿病。
  • 基线平均 AOSBP 149±10.4 mmHg,UACR 几何均值 516.8±2.51 mg/g,胱抑素 C-eGFR 43±15.0 mL/min/1.73 m²。
  • AOSBP 最小二乘均值变化:安慰剂 -1.8 mmHg(95%CI -5.6, 2.1),lorundrostat -9.3 mmHg(-13.1, -5.4),安慰剂校正差 -7.5 mmHg(-12.3, -2.7)。
  • UACR 几何均值安慰剂校正降低 30.5%(-41.0, -18.2),lorundrostat 组降低 25.6%(-37.7, -11.2)。
  • eGFR 在 lorundrostat 组由 42.9±15.2 降至 40.1±16.0 mL/min/1.73 m²,安慰剂组由 42.9±15.1 降至 42.1±15.8 mL/min/1.73 m²。

关键数值与推荐

  • lorundrostat 25 mg/日加用于已使用 SGLT2i 和 RAAS 阻滞剂的患者。
  • 主要终点 AOSBP 安慰剂校正差 -7.5 mmHg(95%CI -12.3, -2.7)。
  • UACR 几何均值安慰剂校正降低 30.5%(95%CI -41.0, -18.2)。
  • 3 例因不良事件停药:高钾血症/CKD 恶化、急性肾损伤、视网膜脱离。

临床怎么用

  • 对于已使用 SGLT2i 和 RAAS 阻滞剂的未控制高血压合并 CKD 及白蛋白尿患者,lorundrostat 可进一步降低血压和白蛋白尿。
  • 使用 lorundrostat 期间需监测 eGFR 和血钾,试验中有因高钾血症/CKD 恶化和急性肾损伤停药者。
  • 白蛋白尿降低的长期心肾获益尚不明确,需更长期研究验证。

局限性

  • 样本量较小(59 例),研究周期短(每段治疗 4 周)。
  • 交叉设计,长期疗效和安全性未评估。
  • 白蛋白尿降低能否转化为持久的肾脏或心血管结局改善尚需更长期研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Dysregulated aldosterone plays an important role in the pathogenesis of hypertension (HTN) and chronic kidney disease (CKD). Lorundrostat, a highly selective aldosterone synthase inhibitor, has demonstrated efficacy and safety for uncontrolled HTN (uHTN) and treatment-resistant HTN in multiple well-controlled clinical trials, although its efficacy in patients with uHTN and CKD is not fully established. METHODS: This was a randomized, double-blind, placebo-controlled, crossover trial of lorundrostat (25 mg/day) added to a sodium-glucose cotransporter-2 inhibitor (SGLT2i) in adults with uHTN, CKD, and albuminuria on stable treatment with a renin-angiotensin-aldosterone system blocker. Participants were randomized to lorundrostat-placebo or placebo-lorundrostat in four-week treatment sequences with a four-week washout period. The primary end point was change in automated office systolic blood pressure (AOSBP). Other endpoints included change in urine albumin-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR). RESULTS: The 59 participants had a mean age of 64.6 years, mean body mass index of 33 kg/m2, and 76% had type 2 diabetes. At baseline, mean AOSBP was 149±10.4 mm Hg, geometric mean UACR (spot) was 516.8±2.51 mg/g, and cystatin C-eGFR was 43±15.0 mL/min per 1.73 m2. Least squares mean change in AOSBP was -1.8 mm Hg (95% Confidence Interval, -5.6, 2.1) with placebo and -9.3 mm Hg (-13.1, -5.4) with lorundrostat (placebo-adjusted, - 7.5 mm Hg (-12.3, -2.7)). Reduction in geometric mean of UACR was 30.5% (-41.0, -18.2) placebo-adjusted, 25.6% (-37.7, -11.2). eGFR decreased from 42.9±15.2 to 40.1±16.0 mL/min per 1.73 m2 with lorundrostat and from 42.9±15.1 to 42.1±15.8 mL/min per 1.73 m2 with placebo. Three participants discontinued treatment due to adverse events (hyperkalemia/CKD worsening, acute kidney injury, and retinal detachment). CONCLUSIONS: Lorundrostat added to SGLT2i reduced AOSBP and albuminuria in patients with uHTN and CKD and was associated with an acceptable safety profile. The observed reduction in albuminuria may suggest a potential cardiorenal benefit. However, longer-term studies are needed to determine whether these findings translate into durable kidney or cardiovascular outcomes. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT06150924.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Weir MR, Bhaduri S, Lee K, et al. Results from the Phase 2 Explore-CKD Trial of lorundrostat, a novel aldosterone synthase inhibitor, in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria. Kidney Int. 2026. PMID: 42778148. doi:10.1016/j.kint.2026.08.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。